U.S. Pharma Stock News

Sana Biotechnology (SANA) is back in focus as CEO Steve Harr prepares to deliver a business overview and company update at the BofA Securities 2026 Healthcare Conference on May 12. See our latest analysis for Sana Biotechnology. At a share price of $3.50, Sana’s 7 day share price return of 6.38% and 30 day share price return of 11.11% contrast with a year to date share price decline of 16.47%. The 1 year total shareholder return of 93.37% sits against weaker 3 and 5 year total shareholder...

In recent weeks, Amer Sports has delivered a run of earnings and revenue beats, outpacing analyst expectations and highlighting especially strong momentum in its premium outdoor brands such as Arc’teryx. What stands out is how Arc’teryx’s expansion into new regions and lifestyle categories is becoming a central engine for Amer Sports’ growth ambitions and margin improvement plans. We’ll now examine how Amer Sports’ consistent earnings outperformance and Arc’teryx-led expansion could...

In late April 2026, FormFactor, Inc. reported first-quarter revenue of US$226.14 million and net income of US$20.38 million, and issued second-quarter guidance calling for revenue around US$240 million and net income per diluted share near US$0.46, alongside expectations for record quarterly revenue and higher margins. Management linked this momentum to strong demand for AI-related semiconductor testing and ongoing restructuring and capacity investments, while FormFactor also highlighted its...

If you are looking at Goosehead Insurance and wondering whether the recent share price puts the stock on sale or still leaves it looking expensive, the starting point is to understand how its current valuation stacks up against its fundamentals. The stock last closed at US$42.12, after recent returns of a 6.0% decline over 7 days, a 5.7% decline over 30 days, a 40.0% decline year to date, and a 58.8% decline over the past year. This naturally raises questions about whether sentiment has...

If you are wondering whether Asana’s current share price reflects its true worth, this breakdown will help you weigh what the market is pricing in against what the fundamentals suggest. Asana’s stock last closed at US$7.05, with a 7 day return of 11.6% and a 30 day return of 13.7%. However, the year to date return of negative 45.6% and 1 year return of negative 59.1% highlight that many holders have faced a tough ride. Those recent moves sit against a backdrop of ongoing coverage around...

Raymond James Financial (NYSE:RJF) has rolled out its Client 360 platform and an artificial intelligence learning academy for financial advisors. The company is committing a reported US$1.1b to technology, including AI powered tools aimed at improving advisor productivity and client service. Raymond James has closed its acquisition of Clark Capital Management Group and introduced proprietary active ETFs to expand its asset management menu. For investors following wealth management and...

What recent performance says about Signet Jewelers (SIG) Without a specific news headline driving the move, Signet Jewelers (SIG) has attracted interest after a period where the stock showed a mix of short term pullbacks and longer term gains. See our latest analysis for Signet Jewelers. At a share price of $87.99, Signet’s recent 1 day and 30 day share price gains contrast with a weaker 90 day share price return. However, the 1 year total shareholder return of 37.84% and 5 year total...

Kodiak Sciences (NasdaqGM:KOD) reported positive Phase 3 GLOW2 results for Zenkuda (tarcocimab tedromer) in diabetic retinopathy. The drug showed superiority over sham treatment, supporting a potential multi indication BLA submission. The update follows earlier focus on KSI-101 and adds fresh validation for Kodiak’s ABC platform in retinal disease. Kodiak Sciences, trading at $43.68, now has clinically meaningful Phase 3 data for Zenkuda that relates directly to its lead pipeline asset. The...

Zoetis (ZTS) has opened 2026 with Q1 revenue of US$2.3b and basic EPS of US$1.42, setting the tone for how investors read the latest earnings update. The company has seen quarterly revenue move from US$2.2b in Q1 2025 to US$2.3b in Q1 2026, while basic EPS shifted from US$1.41 to US$1.42 over the same period, giving you a clear view of how the top and bottom lines are tracking year on year. Against that backdrop, the focus now is on how sustainably Zoetis is converting this revenue into...

If you are wondering whether Royal Gold's current share price reflects its underlying value, this article walks through the key numbers that can help you form an informed view. The stock closed at US$232.62, with returns of 5.2% year to date and 31.3% over 1 year, while the last 30 days show a 10.8% decline and the last 7 days a 0.3% decline. Recent coverage has focused on Royal Gold's long term share price performance and how it compares with the broader materials sector. This helps frame...

Sensata Technologies Holding plc has reported past first-quarter 2026 results showing sales of US$934.8 million and net income of US$87.1 million, alongside new second-quarter guidance and an update on its ongoing share repurchase program. Together, the stronger quarterly earnings, forward earnings guidance, and completion of a multi-year buyback provide fresh insight into how Sensata is balancing growth investment with returning capital to shareholders. Next, we will examine how Sensata’s...

Arcus Biosciences (RCUS) has been in focus after first quarter 2026 results, which showed revenue of US$17 million and a net loss of US$128 million, alongside several pipeline and collaboration setbacks. See our latest analysis for Arcus Biosciences. The share price has been volatile around the recent Q1 2026 update and pipeline news. The 1 month share price return is 12.28% and the 90 day share price return is 17.83%, while the 1 year total shareholder return of 190.50% contrasts with a...

Artificial intelligence in healthcare sits at the crossroads of powerful data, rising care costs, and a world focused on inflation, energy shocks, and supply chain shifts. While oil, rates, and trade headlines pull markets in different directions, AI tools that can improve accuracy, access, and affordability in medicine are drawing close attention. The Transformative AI Healthcare Stocks screener looks for companies using AI to sharpen diagnostics, personalise treatment, streamline clinical...

If you are wondering whether Veradermics’ current share price lines up with its underlying value, this article breaks down what the numbers may indicate about the stock. Veradermics recently closed at US$107.85, with returns of 8.9% over 7 days, 90.2% over 30 days and 185.7% year to date. This puts the current price action firmly in focus for valuation-minded investors. Recent coverage around Veradermics has centered on its position within the Pharmaceuticals industry and how investors are...

If you are wondering whether Valero Energy's strong run has left the stock overpriced or if there is still value on the table, this article breaks down what the current price might actually be telling you. Valero Energy's share price closed at US$236.35, with returns of 43.0% year to date and 99.9% over the last year, even though the stock recorded a 6.4% decline over the past week and a 6.0% decline over the past month. Recent commentary around Valero Energy has focused on its share price...

If you are wondering whether Darling Ingredients at around US$62 is offering fair value or a potential discount right now, this article breaks down what the current price may be implying about the stock. The share price is at US$62.27, with a 3.1% decline over the last 7 days and a 2.0% decline over 30 days, set against a 65.4% gain year to date and an 84.0% return over the past year. This mix of recent pullbacks and longer term gains can change how you think about both upside and...

Recent share performance and earnings context Nordic American Tankers (NAT) has drawn fresh attention after recent share moves, with the stock up about 1.6% over the past day and 5% over the past week. Across longer periods, the stock shows a mixed pattern, with a small decline over the past month but gains over the past 3 months, year to date, and the past year contributing to a market value of about US$1.2b. Against this trading backdrop, investors are focusing on how current earnings of...

Addus HomeCare Corporation recently reported first-quarter 2026 results, with net income rising to US$25.07 million from US$21.23 million and diluted EPS from continuing operations increasing to US$1.36 from US$1.16 a year earlier. Growth was led by the Personal Care and Hospice segments, supported by state rate increases, operational efficiencies, and expansion into Indiana through the HomeCourt Home Care acquisition and another pending deal. Next, we’ll examine how this Personal Care and...

Omega Healthcare Investors (NYSE:OHI) is selling CommuniCare’s skilled nursing assets to lower tenant concentration risk. The move is part of a broader portfolio cleanup that also considers financial pressures at Maplewood and Genesis. The company aims to support dividend stability and overall portfolio health as operator stress continues across the sector. For investors watching NYSE:OHI at a share price of $46.13, this portfolio cleanup follows a very large 3-year return and a 94.0%...

Why Chime Financial stock is back in focus Chime Financial (CHYM) just posted its first GAAP profitable quarter since listing, along with 25% year over year revenue growth, a new Chime Prime membership tier, and a completed US$200 million share repurchase program. See our latest analysis for Chime Financial. Despite reporting its first GAAP profitable quarter and approving US$200 million of buybacks, Chime's 1 day share price return of a 12.5% decline and year to date share price return of a...

In April 2026, Everspin Technologies announced a US$40,000,000, 30‑month subcontract with Amentum Services under a U.S. Navy microelectronics RDT&E program, alongside first‑quarter 2026 results showing higher revenue and a smaller net loss than a year earlier. The deal ties Everspin’s Toggle MRAM process technology directly into U.S. defense supply chains, reinforcing its role as an on‑shore memory partner for critical systems. Next, we’ll examine how this US$40,000,000 defense-focused...

Wondering if ASML Holding at around US$1,516.60 is priced for perfection or still offers value? This article breaks down what the current share price really implies for you. The stock has returned 5.4% over the last week, 16.1% over the last month, 30.3% year to date and 115.6% over the past year, which naturally raises questions about where value and risk now sit. Recent coverage around ASML has emphasized its central role in semiconductor equipment and its importance to chip manufacturing...

Wondering whether Citizens Financial Group stock still offers value after its strong run, or if most of the easy gains are already behind it? This article walks through the key signals you can use to make that call. The stock last closed at US$64.22, with returns of 4.3% over 30 days, 8.1% year to date and 70.0% over 1 year, which can change how the market views both its growth potential and its risk profile. Recent coverage has focused on Citizens Financial Group's positioning as a major US...

Pomerantz LLP has opened an investigation into CarMax (NYSE:KMX) for potential securities fraud or other unlawful business practices. The inquiry follows CarMax's April 14, 2026 decision to lower used car prices and accept higher credit risk in response to an auto affordability crisis. The combination of a pricing shift and looser credit standards raises questions about risk management, disclosure, and long term business impacts. CarMax runs one of the largest used car retail operations in...